Predicting tissue c-Met status using plasma soluble c-Met levels in patients with advanced NSCLC

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Hongfei Gao

Citation

Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518

Authors

H. Gao1, Z. Chen2, A. Li2, J. Yang2, X. Zhang2, Z. Xie2, J. Su2, J. Lin1, Y. Li1, Y. Wu2, Z. Dong2

Author affiliations

  • 1 Guangdong Lung Cancer Institute,guangdong Cardiovascular Institute, Guangdong General Hospital, 510080 - Guangzhou/CN
  • 2 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
More

Resources

Aim/Background

Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression of c-Met protein or amplification of the c-Met gene, but each technique requires a high-quality tissue sample, which may not be available. The aim of this study is to investigate whether plasma soluble c-Met level can be used to predict tissue c-Met status in patients with advanced non-small cell lung cancer (NSCLC).

Methods

In 198 patients with advanced NSCLC, we determined c-Met expression by IHC analysis on tumors. The expression was scored according to MetMAb scoring criteria. Plasma concentration of soluble c-Met protein was measured with a human soluble c-Met quantitative enzyme-linked immunosorbent assay (ELISA) kit, and the predictive values were determined based on the receiver-operating characteristic (ROC) curves analysis.

Results

Of the total 198 patients, 103 (52%) patients were tissue c-Met negative, 95(48%) were tissue c-Met positive. The average plasma c-Met concentration was 682.8 ± 155.2 ng/mL in the tissue c-Met-negative group, significantly lower than 886.5 ± 307.4 ng/mL in tissue c-Met- positive group (P < 0.001). ROC curve analysis showed 66.9% specificity and 64.2% sensitivity for predicting tissue c-Met positivity at 755ng/mL of plasma c-Met. AUC for plasma c-Met was 0.724 (95% confidence interval; 0.654–0.794, P < 0.001).

Conclusions

We suggest 755 ng/mL in the plasma as a cutoff for predicting tissue c-Met status with moderate specificity and sensitivity. This information may be useful when the tumour tissue is not available.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings